From Moth to Medicine

From the Cecropia Moth to the Clinic: An Engineered Antimicrobial Peptide Takes On the World's Most Stubborn Superbug

Few molecules better illustrate the arc of modern peptide science than the one now moving through hospital wards in a set of multinational clinical trials. Its name is OMN6, and its story begins not in a pharmaceutical lab but in the immune system of a moth.

OMN6 is the lead clinical candidate of Omnix Medical, a biotechnology company founded in Jerusalem in 2015. The reason it is in the news is a fresh vote of confidence from Europe: in 2026 the company was awarded roughly €8 million, approximately $9.15 million, from the EU's Horizon Europe program to accelerate OMN6's clinical development, its second EU-funded initiative for the candidate. The grant does not fund Omnix alone. It supports a multinational research consortium whose members include the Medical University of Vienna, the National and Kapodistrian University of Athens, the European Clinical Research Alliance on Infectious Diseases, Ecraid, and the French firm Vivexia, the money earmarked to speed patient recruitment and push the program toward Phase III.

That grant lands at a pivotal moment. In June 2026 the company announced that the first patients had been dosed in a Phase IIa trial of OMN6 for hospital-acquired and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii, CRAB, a pathogen the World Health Organization ranks among its critical-priority targets, and one whose mortality in vulnerable patients can approach 60 percent. The EU award also caps a run of financial validation: a $25 million Series C round in late 2025 co-led by Harel Insurance & Finance and the European Innovation Council, EIC, Fund, on top of earlier support from the U.S. National Institutes of Health and the Israel Innovation Authority.

A Familiar Peptide, Re-Engineered

For the peptide community, the most recognizable part of the OMN6 story is its parentage. OMN6 is a 40-amino-acid cyclic peptide based on Cecropin A — and Cecropin A is about as canonical as antimicrobial peptides get. It was first isolated at the dawn of the field, in the early 1980s, by Hans G. Boman and colleagues at Stockholm University, who purified it from the pupae of the giant silk moth Hyalophora cecropia. Boman's work established the very idea that animals defend themselves with gene-encoded antibacterial peptides, and the cecropins became one of the founding families of what is now a vast and well-studied class of host-defense molecules.

Cecropin A kills Gram-negative bacteria by forming an amphipathic α-helix that inserts into and disrupts the bacterial membrane, a physical, non-enzymatic mechanism that makes classical resistance difficult to evolve. The catch, and the reason cecropins never became drugs, is fragility: like most natural peptides, Cecropin A is degraded almost immediately by proteases in the body.

That is where OMN6 diverges from its ancestor. As described in the company's 2021 paper in Scientific Reports, the molecule is a cyclized Cecropin A analog, closed through a disulfide bond between terminal cysteine residues. The cyclization dramatically slows proteolytic degradation while preserving the membrane-disrupting helix. In vitro and in animal studies, OMN6 retained potent activity against multidrug-resistant and even colistin-resistant A. baumannii, with minimum inhibitory concentrations in the low single-digit µg/mL range, showed no meaningful activity against Gram-positive bacteria, consistent with a targeted Gram-negative mechanism, and produced no cytotoxicity or hemolysis against human cells at the concentrations tested. In short, it behaves like Cecropin A where you want it to and unlike Cecropin A where you don't.

Familiar Institutions and Labs

The scientific and clinical advisory bench reinforces the point. Omnix's scientific advisory includes Prof. Roger D. Kornberg of Stanford University, who won the 2006 Nobel Prize in Chemistry for his work on the molecular basis of eukaryotic transcription. Antibacterial drug-discovery is guided by Dr. Lynn L. Silver, a widely cited authority on the economics and biology of antibiotic R&D, while the medical and clinical advisory roles draw on infectious-disease leaders including Prof. Yehuda Carmeli of the Tel Aviv Sourasky Medical Center, a global figure in antimicrobial-resistance epidemiology, and Prof. Keith Kaye of Rutgers Robert Wood Johnson Medical School.

Why it matters

The pipeline for antibiotics active against Gram-negative "superbugs" is famously thin, and CRAB sits near the top of the global watch list precisely because so few options remain. Antimicrobial peptides have been discussed as a solution for four decades, ever since Boman's moth studies, but stability, toxicity, and manufacturing have repeatedly stalled them short of the clinic. OMN6 is interesting not because it introduces a new mechanism, but because it takes one of the field's oldest and best-characterized molecules and engineers around the exact liabilities that held the class back. For anyone who has followed antimicrobial peptides from the bench, watching a cyclized Cecropin A analog enter randomized, placebo-controlled human trials is a notable moment: the founding chemistry of the field, finally being tested where it counts.

Whether OMN6 ultimately reaches patients will depend on Phase II and, eventually, Phase III data. But the trajectory, from a moth's immune peptide characterized in an academic lab in the 1980s, to a chemically stabilized clinical candidate advised by a Nobel laureate and funded across three continents, is a compact history of how peptide science moves from discovery to medicine.